JP2010042007A5 - - Google Patents

Download PDF

Info

Publication number
JP2010042007A5
JP2010042007A5 JP2009211970A JP2009211970A JP2010042007A5 JP 2010042007 A5 JP2010042007 A5 JP 2010042007A5 JP 2009211970 A JP2009211970 A JP 2009211970A JP 2009211970 A JP2009211970 A JP 2009211970A JP 2010042007 A5 JP2010042007 A5 JP 2010042007A5
Authority
JP
Japan
Prior art keywords
cells
kda
activated
lymphocytes
measured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009211970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010042007A (ja
JP5021008B2 (ja
Filing date
Publication date
Priority claimed from DE19821060A external-priority patent/DE19821060A1/de
Application filed filed Critical
Publication of JP2010042007A publication Critical patent/JP2010042007A/ja
Publication of JP2010042007A5 publication Critical patent/JP2010042007A5/ja
Application granted granted Critical
Publication of JP5021008B2 publication Critical patent/JP5021008B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2009211970A 1997-09-23 2009-09-14 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用 Expired - Fee Related JP5021008B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19741929 1997-09-23
DE19741929.1 1997-09-23
DE19821060.4 1998-05-11
DE19821060A DE19821060A1 (de) 1997-09-23 1998-05-11 Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000512857A Division JP4463418B2 (ja) 1997-09-23 1998-09-23 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用

Publications (3)

Publication Number Publication Date
JP2010042007A JP2010042007A (ja) 2010-02-25
JP2010042007A5 true JP2010042007A5 (cg-RX-API-DMAC7.html) 2010-12-09
JP5021008B2 JP5021008B2 (ja) 2012-09-05

Family

ID=7843330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009211970A Expired - Fee Related JP5021008B2 (ja) 1997-09-23 2009-09-14 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用

Country Status (3)

Country Link
US (6) US7132099B2 (cg-RX-API-DMAC7.html)
JP (1) JP5021008B2 (cg-RX-API-DMAC7.html)
DE (1) DE19821060A1 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP4463418B2 (ja) * 1997-09-23 2010-05-19 ドイツ連邦共和国 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
AU1102000A (en) * 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
EP2332976B1 (en) * 1999-02-03 2014-04-02 Amgen, Inc Novel polypeptides involved in immune response
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
DE19936035C2 (de) * 1999-07-30 2002-11-21 Univ Leipzig Lymphozytenproliferationstestkit
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20050164260A1 (en) * 2003-12-30 2005-07-28 Sigma-Aldrich Co. Rapid preparation of nucleic acids by enzymatic digestion
AU2005235718B2 (en) 2004-04-23 2011-09-22 Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo
WO2011041613A2 (en) * 2009-09-30 2011-04-07 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
CA2791975C (en) 2010-02-04 2021-02-09 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
KR102023661B1 (ko) * 2011-03-31 2019-09-23 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Icos에 대한 항체 및 이의 용도
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
MA53297A (fr) 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
US10968277B2 (en) 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル-マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
UA129038C2 (uk) 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型cdcp1に対する抗体およびその使用
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
KR900702370A (ko) 1988-10-06 1990-12-06 제임스 디. 그랜트 가용성 t세포 표면분자를 사용하는 치료 및 진단방법
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP4463418B2 (ja) 1997-09-23 2010-05-19 ドイツ連邦共和国 T細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
AU1102000A (en) * 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
EP2332976B1 (en) * 1999-02-03 2014-04-02 Amgen, Inc Novel polypeptides involved in immune response
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤

Similar Documents

Publication Publication Date Title
JP2001517425A5 (cg-RX-API-DMAC7.html)
JP7270001B2 (ja) Mhcクラスii拘束性mage-a3を認識するt細胞受容体
Auerbach et al. Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor
Picchianti Diamanti et al. Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: the fragile balance between infections and autoimmunity
Gogishvili et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
Sakkas et al. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis—relevance to treatment
US20210077566A1 (en) Peptides Having Anti-Inflammatory Properties
Ríos-Ríos et al. T cells subsets in the immunopathology and treatment of Sjogren’s syndrome
ES2353273T3 (es) Anticuerpos anti-cd28.
Cortez et al. CRTAM controls residency of gut CD4+ CD8+ T cells in the steady state and maintenance of gut CD4+ Th17 during parasitic infection
Tu et al. Efficient osteoclast differentiation requires local complement activation
Praveen et al. Constitutive expression of tumor necrosis factor-alpha in cytotoxic cells of teleosts and its role in regulation of cell-mediated cytotoxicity
WO2015022520A1 (en) T cell receptors
V. Reiche et al. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1)
Lee et al. Immune Evasion by Kaposi‘s Sarcoma-Associated Herpesvirus
RU2018140056A (ru) Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена
ES2710444T3 (es) Un polipéptido de interleucina 34 aislado para uso en la prevención del rechazo de trasplante y el tratamiento de enfermedades autoinmunitarias
JP6792559B2 (ja) 癌治療のためのhlaホモ二量体の使用
Del Bello et al. Immune checkpoints in solid organ transplantation
Moritz et al. Molecular studies reveal that A134T, G156A and G1333A SNPs in the CD177 gene are associated with atypical expression of human neutrophil antigen‐2
Ravindranath et al. Four faces of cell-surface HLA class-I: their antigenic and immunogenic divergence generating novel targets for vaccines
TW202328196A (zh) 使用vista抗原結合分子的癌症之治療及預防
Ciszak et al. Alterations in the expression of signal-transducing CD3ζ chain in T cells from patients with chronic inflammatory/autoimmune diseases
Socié et al. Immune biology of allogeneic hematopoietic stem cell transplantation: models in discovery and translation
CN116790737B (zh) Pik3ip1蛋白在制备诊断或治疗自身免疫性疾病的试剂或药物中的应用